Loading...
•
Sep 30, 2021
Bicycle Q3 2021 Earnings Report
Reported third quarter financial results and provided corporate update.
Key Takeaways
Bicycle Therapeutics reported financial results for the third quarter ended September 30, 2021, highlighting progress in clinical trials for BT5528 and BT8009, advancement of BT7480 into the clinic, and expansion of the Genentech collaboration.
Provided a clinical update for ongoing Phase 1 dose escalation trials in BT5528 and BT8009.
Observed preliminary anti-tumor activity in both trials across two tumor types.
BT7480, a Bicycle TICA™, recently entered the clinic.
Expanded partnership with Genentech to include a new program.
Forward Guidance
Bicycle Therapeutics anticipates further advancements in its product candidates, including BT5528, BT8009 and BT7480, and the continued progression of clinical trials.
Positive Outlook
- Anticipated advancement of its product candidates
- Advancement of Bicycle’s product candidate pipeline
- Initiation of enrollment in and progression of Bicycle’s and its collaboration partners’ clinical trials
- Availability and timing of data from clinical trials
- Potential to receive milestone payments and royalties under its license and collaboration agreement with Ionis
Challenges Ahead
- Risks to site initiation, clinical trial commencement, patient enrollment and follow-up presented by the ongoing COVID-19 pandemic
- Uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Bicycle’s product candidates by Bicycle or its collaboration partners
- Risk that Bicycle may not realize the intended benefits of its technology
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...